Confirmed Speaker Faculty for EA3, January 2020
Paul Aliu, PharmD Global Head of Medical Governance, Novartis Oncology
Chris Austin, MD Director, National Center for Advancing Translational Sciences, NIH
Behtash Bahador Director, Center for Information and Study on Clinical Research Participation (CISCRP)
Amy Barone, MD Medical Officer, Oncology Center of Excellence, FDA
Naomi Lopez Bauman Director of Healthcare Policy, Goldwater Institute
Chris Beardmore CEO, Anova LLC
Stuart Bell, PhD Vice President, Real World Evidence, Inceptua Medicines Access
Amar Bhat, PhD Interim Executive Director, Reagan-Udall Foundation, FDA
Mark Boutin Chief Executive Officer, National Health Council
Suanna Bruinooge, MPH Director of Research Strategy, CENTRA, ASCO
Anne Cropp, PharmD Chief Scientific Officer, Early Access Care, LLC
Jonathan Darrow, JD Faculty Member, Harvard Medical School
David Farber, JD Senior Partner, King & Spalding
Tony Fauci, MD Director, National Institute of Allergy and Infectious Diseases (NIAID) 1984-Present
Christina Hartman, MPH Senior Director, Advocacy & Policy, EveryLife Foundation for Rare Diseases
Richard Klein Former Director, Patient Liaison Program, FDA
Marcel van Kuijck, PhD Vice President, Global Medical Affairs, Ultragenyx
Michael Kurilla, MD, PhD Director, Clinical and Translational Science Awards (CTSA) Program, NCATS, NIH
Jeff Leider President, X2, “Let Them Be Little” Foundation
Alexander Natz Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Peter Pitts President, Center for Medicine in the Public Interest
Jess Rabourn, CFA Executive Producer, Expanded Access Summit | CEO, WideTrial, Inc.
Kelly Ranallo President, Turner Syndrome Global Alliance; Associate, Rare Diseases, Sanofi
David Schwicker Principal and Founder, ORPHA Strategy Consulting
Erika Segear, PhD, RAC Associate Director of Regulatory Affairs, Duke University School of Medicine
Andrew Shuman, MD, FACS Chief of Clinical Ethics Services, University of Michigan Medical School
Marjorie Speers, PhD Executive Director, Clinical Research Pathways
Steve Usdin Senior Editor, BioCentury
Kevin Weatherwax Managing Director, Michigan Institute for Clinical and Health Research, University of Michigan Health SystemJanet Woodcock, MD Director, Center for Drug Evaluation and Research (CDER), FDA
Frank Young, MD, PhD EVP Clinical & Reg Affairs, TissueTech Inc.; Former FDA Commissioner, 1984-1989
Chris Austin, MD
Christopher P. Austin has served as director of the National Center for Advancing Translational Sciences at the National Institutes of Health since 2012. Prior to this role, he was NCATS’ scientific director, focusing on translating basic science discoveries into new treatments and technologies to improve the efficiency of therapeutic/diagnostic development. He founded several initiatives, including the NIH Chemical Genomics Center, the Therapeutics for Rare and Neglected Diseases program, and the Toxicology in the 21st Century program.
Before joining NIH in 2002, he led genomic-based target discovery, pharmacogenomic, and neuropsychiatric drug-development programs at Merck. From 2016 to 2018, he served as chair of the International Rare Disease Research Consortium (IRDiRC); Dr. Austin is also a member of National Academy of Medicine.
He earned an A.B. from Princeton University, an M.D. from Harvard Medical School, and completed training in internal medicine and neurology at Massachusetts General Hospital.
Amy Barone, MD
Naomi Lopez Bauman
Stuart Bell, PhD
Amar Bhat, PhD
Marc Boutin, JD
Marc M. Boutin, JD, is the Chief Executive Officer of the National Health Council. He has been a leading voice for greater patient involvement at every stage of the health care continuum, starting with the development of new drugs, to regulatory oversight of health care delivery, to shared decision-making at the point of care.
Under his leadership, the National Health Council has convened a broad range of stakeholders to create and effectively implement pragmatic strategies and public policy that address diverse issues, such as enhancing patient engagement, advancing the development of new treatments, and developing a better health delivery system to meet the needs of people with chronic conditions.
Boutin has a long history of board and committee service. Currently, he serves as a member of the Patient-Centered Outcomes Research Institute (PCORI) Patient Engagement Advisory Panel, FasterCures Benefit-Risk Advisory Council, and the Medical Device Innovation Consortium (MDIC) Patient-Centered Benefit-Risk Steering Committee.
Boutin has been actively involved in patient advocacy organization management, health advocacy, and both federal and state policy throughout his career. He is a founding member of the international Patient-Focused Medicine Development consortium and has served on the Governing Board of the International Alliance of Patients’ Organizations as a member and treasurer. He is also a former member of the Partnership to Fight Chronic Disease Board of Directors, the Humana Cares Clinical Advisory Board, the eHealth Initiative Leadership Council, Community Health Charities Board of Directors, Healthcare Systems Research Collaboratory, and the North America Advisory Board to the Drug Information Association.
Suanna Bruinooge, MPH
Anne Cropp, PharmD
Jonathan Darrow, JD
David Farber, JD
Toni Fauci, MD
Anthony S. Fauci, M.D. is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio focused on infectious and immune-mediated diseases. He serves as one of the key advisors to the White House and Department of Health and Human Services on global HIV/AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats.
He is the winner of numerous prestigious awards including the Presidential Medal of Freedom, the National Medal of Science and the Lasker Award for Public Service.
Christina Hartman, MPH
Marcel van Kuijck, PhD
Michael Kurilla, MD, PhD
Director of the Division of Clinical Innovation, NCATS-NIH
Michael Kurilla is the director of the Division of Clinical Innovation at NCATS (National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)). In this capacity, he oversees the Clinical and Translational Science Awards (CTSA) Program, which supports innovative solutions to advance the efficiency, quality and impact of translational science, with the ultimate goal of getting more treatments to more patients more quickly.
Prior to joining NCATS, Kurilla served as the director of the Office of Biodefense Research Resources and Translational Research within the National Institute of Allergy and Infectious Diseases (NIAID), where he focused on translational efforts toward infectious disease product development, including vaccines, therapeutics and diagnostics, with emphasis on biodefense and emerging infectious disease threats.
Prior to joining NIAID in 2003, Kurilla was an associate director for infectious diseases at Wyeth. He also worked in antimicrobials at DuPont and on clinical microbiology and molecular pathology at the University of Virginia Health Sciences Center.
Kurilla received his M.D. and his Ph.D. in microbiology and immunology from Duke University. He was a postdoctoral research fellow at Harvard Medical School and completed a residency in pathology at Brigham and Women’s Hospital. He received a B.S. in chemistry from the California Institute of Technology.